Aernoud Fiolet

152 Chapter 5 Table S4 Baseline Characteristics of the Trial Participants Stratified by Country* Characteristic Australia (N=1904) The Netherlands (N=3618) Age – yr 67.1 ± 8.4 65.1 ± 8.6 Female sex – no. (%) 252 (13.2%) 594 (16.4%) Current smoker – no. (%)† 80 (4.2%) 568 (15.7%) Hypertension – no. (%) 1025 (53.8%) 1783 (49.3%) Diabetes – no. (%) Any treatment 345 (18.1%) 662 (18.3%) Insulin dependent – no. (%) 96 (5.0%) 191 (5.3%) Renal function‡ Stage 1, 2 – no. (%) 1884 (98.9%) 3332 (92.1%) Stage 3a – no. (%) 20 (1.1%) 286 (7.9%) Prior acute coronary syndrome – no. (%) 1532 (80.5%) 3126 (86.4%) Time since last acute coronary syndrome ≤ 24 months – no. (%) 385 (20.2%) 1094 (30.2%) > 24 months – no. (%) 1147 (60.2%) 2032 (56.2%) Prior coronary revascularization – no. (%) 1415 (74.3%) 3206 (88.6%) Coronary artery bypass grafting – no. (%) 270 (14.2%) 440 (12.2%) Percutaneous coronary intervention – no. (%) 1241 (65.2%) 2936 (81.1%) History of atrial fibrillation – no. (%) 190 (10.0%) 459 (12.7%) History of gout – no. (%) 162 (8.5%) 284 (7.8%) Medication use Single antiplatelet therapy – no. (%) 1266 (66.5%) 2435 (67.3%) Dual antiplatelet therapy – no. (%) 551 (28.9%) 729 (20.1%) Anticoagulant – no. (%) 154 (8.1%) 518 (14.3%) No antiplatelet agent or anticoagulant – no. (%) 4 (0.2%) 11 (0.3%) Statin – no. (%) 1838 (96.5%) 3350 (92.6%) Ezetimibe – no. (%) 221 (11.6%) 852 (23.5%) Any lipid-lowering agent – no. (%) 1865 (98.0%) 3470 (95.9%) Renin angiotensin inhibitor – no. (%) 1403 (73.7%) 2557 (70.7%) Beta-blocker – no. (%) 991 (52.0%) 2436 (67.3%) Calcium-channel blocker – no. (%) 466 (24.5%) 778 (21.5%) * Plus-minus values are means and standard deviation. † For 21 participants information on smoking was missing. ‡ Stage 1 refers to an estimated glomerular filtration rate of ≥ 90 ml/min per 1.73m² (normal or high), stage 2 to 60-89 ml/min per 1.73m² (mildly decreased), and stage 3a to 45-59 ml/min per 1.73m² (mildly to moderately decreased). Stages are based on the Clinical Practice Guideline of Kidney Disease: Improving Global Outcomes (KDIGO) 2